← 홈

프로그램 비교

검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일

현재 선택: 1

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

API CSV20행 · 1개 프로그램

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목
AntibodyPhase 2
polymerase chain reaction (polymerase chain reaction)
OSI Pharmaceuticals·FRα
ORR 3%
Overview
Program
polymerase chain reaction
Overview
Company
OSI Pharmaceuticals
Overview
Modality
ANTIBODY
Overview
Target
FRα
Overview
Indication
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Overview
Phase
PHASE_2
Overview
Status
ACTIVE
MoA
Biomarker
Biomarkers for Breast Cancer: A Case-Control Study
PK/PD
Species
Mouse, Consequently
PK/PD
Animal (cat.)
Mouse
PK/PD
Experiment
Pharmacokinetic
Toxicology
Species
Mouse, Consequently
Toxicology
Animal (cat.)
Mouse
Toxicology
Major finding
Guggulsterone Alleviates Atherosclerosis in ApoE -/- Mice by Modulating Lipid Metabolism and Inflammatory Responses Associated with Modulation of the Srebp2 / Hmgcr Signaling Axis.. Atherosclerosis (AS) is a chronic inflammatory vascular disease characterized by dysregulated lipid homeostasis and plaque formation. Consequently, there is an ongoing need for therapies with high efficacy and low toxi…
Clinical
Primary efficacy
ORR 3%
Clinical
ORR
3%
Clinical
Result source
ClinicalTrials.gov NCT01557959
Clinical
Data Tier / Score
A · 32
Clinical
Program phase
PHASE_2
Clinical
Clinical sync
2026년 7월 8일 (6일 전)